<DOC>
	<DOCNO>NCT02011958</DOCNO>
	<brief_summary>The overall objective trial identify safe effective treatment visceral leishmaniasis ( VL ) HIV co-infected Ethiopian patient . Patients receive either Ambisome alone Ambisome combination Miltefosine . Patients undergo treatment failure give VL prophylactic treatment Pentamidine one month end study treatment .</brief_summary>
	<brief_title>Efficacy Trial Ambisome Given Alone Ambisome Given Combination With Miltefosine Treatment VL HIV Positive Ethiopian Patients .</brief_title>
	<detailed_description>Visceral Leishmaniasis ( VL ) neglect disease fatal left untreated . Ethiopia one country majority case occur . With spread HIV VL endemic area increase co-infected case report Ethiopia . HIV VL mutually influence affect cellular immunity . The important feature co-infection include poor outcome , increase drug toxicity relapse treatment need maintenance therapy . There study co-infected patient . There specific recommendation HIV-VL co-infected patient Ethiopia . This protocol evaluate efficacy safety combination Ambisome Miltefosine Ambisome monotherapy ( high dose ) Ethiopia . It design randomise , parallel arm , open-label trial . No comparator include . The randomization stratify accord centre well wether VL primary case relapse . The study analyse accord group-sequential method , specifically triangular test . Data arm analyse every 10 patient reach primary endpoint final cure day 29 . The data analyse proportion accord intention treat per protocol analysis arm.In order address potential heterogeneity population , test perform treatment stop . Depending outcome test heterogeneity , recruitment may continue one stratum . The treatment duration 28 day 56 day case extend treatment . - If Day 29 assessment , tissue aspirate parasite negative , patient eligible secondary prophylaxis ( Pentamidine 4mg/kg IM ( intramuscular ) month maximum 18 month ) enter 1 year follow phase . - If day 29 assessment , tissue aspirate positive patient well , he/she receive another complete course treatment ( classified treatment failure ) . The patient evaluate day 58 . Those still parasite positive tissue aspirate offer rescue treatment . Those negative offer secondary prophylaxis eligible ( Pentamidine 4mg/kg IM month maximum 18 month ) . - If day 29 assessment , tissue aspirate positive patient unwell , he/she treat rescue treatment ( consider treatment failure ) - All patient , independently outcome day 29 and/or day 58 enter follow-up assessment day 210 day 390 . Rescue treatment also give case relapse follow-up period case occurence severe grade 2 grade 3 PKDL PKDL mucosal and/or eye involvement treatment period . All patient yet antiretroviral treatment ( ART ) inclusion commence ART complete routine voluntary counsel testing procedure . Patients already ART diagnosis VL continue ART throughout study .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Confirmed HIV positive test ( 2 rapid diagnostics test ( RDTs ) follow confirmatory ELISA test ) . Diagnosis VL ( first episode relapse ) confirm bone marrow spleen aspirate . Male female age : 1860 year . Written informed consent patient . Women childbearing potential ( defined woman achieve menarche ) use assure method contraception unwilling use assure method contraception duration treatment four month . Pregnant woman breastfeed mother . Patients grade 2 3 post kalaazar dermal leishmaniasis ( PKDL ) lesion . Clinical biological evidence severe cardiac , renal hepatic impairment . Known hypersensitivity AmBisomeÂ® and/or miltefosine . Patients receive allopurinol treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Visceral Leishmaniasis</keyword>
	<keyword>HIV positive patient</keyword>
	<keyword>Phase III trial</keyword>
	<keyword>Randomised</keyword>
	<keyword>Liposomal amphotericin B</keyword>
	<keyword>Ambisome</keyword>
	<keyword>Miltefosine</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>